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After trauma brain injury, oxidative substances released to the medium provoke an enlargement of the initial lesion, increasing
glial cell activation and, occasionally, an influx of immune cells into the central nervous system, developing the secondary damage.
In response to these stimuli, microglia are activated to perform upregulation of intracellular enzymes and cell surface markers to
propagate the immune response and phagocytosis of cellular debris. The phagocytosis of debris and dead cells is essential to limit
the inflammatory reaction and potentially prevent extension of the damage to noninjured regions. Lipoic acid has been reported
as a neuroprotectant by acting as an antioxidant and anti-inflammatory agent. Furthermore, angiogenic effect promoted by lipoic
acid has been recently shown by our group as a crucial process for neural regeneration after brain injury. In this work, we focus our
attention on the lipoic acid effect on astroglial and microglial response after brain injury.
1. Introduction
Traumatic brain injury (TBI) is a complex process involving
a broad spectrum of symptoms and long-term consequences
including disabilities [1]. As a consequence of the primary
insult, many molecules from injured and dead cells induce
microglial and astroglial activation [2] and disruption of
the blood-brain barrier (BBB) [3]. In addition to the direct
loss of tissue caused by the trauma, secondary mechanisms
leading to additional tissue injury are important for out-
come and therefore constitute important therapeutic targets
[4].
Recently, interest has been focused on oxidative stress
as a mechanism involved in the development of secondary
brain damage [5]. After brain injury, a local increase in
glial cell activation occurs and, occasionally, an influx of
immune cells goes into the central nervous system (CNS).
Accumulation of blood born immune cells at the side of the
lesion is paralleled by activation of CNS-resident astrocytes
and microglia, where they latter transform into phagocytic
macrophages [6].
The use of lipoic acid (LA) on stroke and TBI animal
models seems to be effective, restoring the BBB disruption
and normalizing the astrocytic/microglial activation and
glutathione (GSH) levels [7–9]. LA is well known as a
natural cofactor for mitochondrial enzymes and is critical
in breaking down fatty acids, which further enhance cellular
energy efficiency. Recent findings obtained by our group
show that LA works as a good neuroprotectant by acting
as an antioxidant, increasing the antioxidant capacity of
the tissue, decreasing the astroglial reaction, as well as the
glial scar formation, promoting angiogenesis, and switching
the regulation of several genes linked to cell survival and
plasticity [10], but the microglial response is still unclear.
New controversies have also emerged such as the question
of whether microglia are active or reactive players in neu-
rodegenerative disease conditions. Some studies have been
done to differentiate the inflammatory response from other
biochemical processes in the development of secondary brain
injuries and to explore what pathways in the inflammatory
response mediate detrimental and/or protective effects fol-
lowing TBI [5]. It is now accepted that microglial cells can
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be acutely blood-derived in the adults under certain patho-
logical conditions [11]. In that sense, microglial cells have the
potential to develop into full-blown macrophages [12].
Since local microglia, astrocytes, and infiltrated
macrophages are the main effectors of the innate immune
response in the CNS [4], understanding the process of glial
response is critical for formulating effective preventive and
therapeutic strategies against brain injuries [13]. For that
reason, the aim of the present work is to study the long-term
astroglial and microglial response when LA treatment is
administered after brain injury.
2. Experimental Procedures
2.1. Experimental Animal Models. Adult male Wistar rats
(Harlan, Italy) weighing 250 ± 25 g were housed (two rats
per box) one week before starting the experiment. Rats were
housed in controlled conditions of temperature (20∘C) and
humidity (60%), under constant light-dark cycles of 12 hours.
Handling and care of animals were done according to the
Real Decreto 1201/05 and supervised and approved by the
Committee of Ethics and Experimental Procedures of the
Universidad CEU-Cardenal Herrera. Unnecessary stress or
pain was avoided as possible.
2.1.1. Surgery and Brain Cryoinjury. Rats were anesthetized
with a mixture of ketamine (12mg/kg), acepromazine
(0.4mg/kg), and fentanyl (0.02mg/kg) that was injected
intraperitoneally (i.p.). Once deeply anesthetized, rats were
placed in a stereotaxic frame. The dorsal part of the skull
was exposed and a craniotomy (2mm of diameter) was
drilled on stereotaxic coordinates anteroposteriorly, 0mm
from bregma, and laterally, 1.5mm from medial line [14].
The brain cryoinjury was performed following the protocol
described by Quintana et al. [15]. Thus, the cryoinjury (1mm
deep) was performed in the cerebral cortex by using a
stainless steel probe (1mm ø) previously frozen in liquid
nitrogen. The frozen probe was maintained within the brain
tissue for 20 sec. Finally, animals were sutured with a skin
stapler (6.9× 3.6mmstaples) and amixture of buprenorphine
(0.015mg/kg) and metamizol (20mg/kg) was i.p. adminis-
tered after surgery.
Another group of rats were anesthetized, and the protocol
described before was carried out (including the craniotomy),
but rats were not cryoinjured. This group was considered as
control group.
2.1.2. Experimental Groups and LA Administration. Cryoin-
jured rats were randomly selected immediately after the
surgery. One group (𝑛 = 12) received a daily dose (100mg/kg
i.p inNaCl 0.9%) of LA (SigmaAldrich, Spain) for 7 days (CR
+ LA), starting the same day of surgery and the other group
(𝑛 = 12) received the same volume of saline solution (NaCl
0.9% i.p.) for the same period of time (CR). Noncryoinjured
rats (𝑛 = 12) received the same volume of saline (control).
2.1.3. Sacrifice and Tissue Preparation. One pool of animals
was housed for 15 days and then sacrificed by an i.p. overdose
of pentobarbital (0.2 g/kg). Another pool was housed for 60
days and was sacrificed in the same way.
Once sacrificed, animals of 15 and 60 days (𝑛 = 6 for
each group) were intracardially perfused with 100mL of
saline solution followed by 200mL of 4% paraformaldehyde
(PFA) in saline solution pH 7.5. Brains were removed and
postfixed in the same fixative solution for 24 h at 4∘C. Then,
brains were cryoprotected by immersion in sucrose 30% in
phosphate buffer saline (PBS) 0.01MpH 7.1 solution for five
days also at 4∘C. Sections of 20𝜇m thickness were serially
obtained with a cryostat (Leica) and mounted in glass slides.
Sections were stored at −80∘C.
2.2. Cytological Study
2.2.1. Hematoxylin-Eosine Staining. Haematoxylin-eosin
staining was performed for histological characterization of
the injured area by using brain sections from LA treated
(CR + LA) and not treated animals (CR) at 60 days.
2.2.2. Immunofluorescence. Sections were selected and
washed three times with PBS 0.1M for 5min at room temper-
ature, blocked for 2 h with 20% fetal bovine serum (FBS) in
PBS-Triton 0.1%, and incubated at 4∘C overnight with pri-
mary antibodies: anti-Collagen IV (1 : 200, Abcam, UK);
anti-glial fibrillary acidic protein (GFAP) (1 : 500, Dako
Cytomation, Denmark); and anti-CD68 (ED1) (1 : 200, AbD
Serotec, UK).
Alexa Fluor 488 IgG (H + L) (1 : 200, Invitrogen, Spain)
and Alexa Fluor 555 IgG (H + L) (1 : 200, Invitrogen, Spain)
antibodies were used as secondary antibodies incubating for
2 h at room temperature in darkness. Afterwards, sections
were mounted with DAPI Vectashield (Vector Laboratories,
UK) and images were taken with a Leica Confocal Micro-
scope.
2.2.3. Immunocytochemical Staining. Sections were selected
and rinsed for three times in PBS 0.1MpH 7.5. In order to
block unspecific binding sites and endogenous peroxidase,
sections were incubated in darkness for 15min in a solution
of 3% H
2
O
2
-10% Methanol in PBS-Triton 0.1%. Afterwards,
sections were incubated overnight at 4∘C with specific pri-
mary antibody anti-rabbit Iba1 (Wako Chemicals, Germany)
and 20% FBS in PBS-Triton 0.1% (1 : 200).Then sections were
incubated with biotinylated goat anti-rabbit IgG antibody
(1 : 200, Vector Lab, UK) in darkness for 2 h. After being
washed three times in PBS, sections were incubated with
avidin-biotin-peroxidase complex (Vector Lab, UK) for 1 h.
Staining was developed with DAB (Vector Lab, UK) for time
enough to make visible the marked cells. The reaction was
stopped then bywashingwith distilledH
2
Oand sectionswere
washed with PBS to remove the excess. Finally, sections were
dehydrated and coverslipped and images were taken with a
Leica microscope.
2.3. Quantification and Statistical Analysis. Immunocyto-
chemical and immunofluorescence images were quantified
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Figure 1: Hematoxylin-eosine staining of the injury area 60 days after the brain cryoinjury in untreated animals (a) and LA treated animals
(b). Arrows indicate the edge of the injury. Scale bar: 500 𝜇m.
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Figure 2: Immunofluorescence for GFAP (astrocytes in green) in nontreated animals (a) and LA treated animals (b), 60 days after the brain
cryoinjury. Nuclei become evident with Dapi (blue). Quantification of astrocyte cell density (n∘ cells/mm2) (c) Scale bar: 50𝜇m. ∗𝑃 < 0.05.
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Figure 3: Immunofluorescence for GFAP (astrocytes in red) and Collagen IV (blood vessels in green) in control animals (a), nontreated
animals (b), and LA treated animals (c) Nuclei become evident with Dapi (blue). Quantification of the density of contacts (n∘ contacts/mm2)
established between astrocytes and blood vessels (d) and the total length of the contacts (𝜇m). (e) Scale bar: 20 𝜇m. ∗∗𝑃 < 0.01; ∗∗∗𝑃 < 0.001.
with ImageJ 1.44i for Mac. The quantifications were per-
formed in the first 500𝜇m from the injury limit. Six images
were randomly taken of 4 sections of each animal (𝑛 = 6) and
the number of cells was determinate by the nuclei presence
and referred to the total area quantified (n∘ cells/mm2).
The number and length of the contacts were quantified
with the program Leica LAS AF Lite for Windows Vista.
Images were randomly taken of the first 500𝜇m from the
injury limit of different zones around the injured area.
Regions of interest (ROIs) were identified when both colour
markers (red and green) were overlapped. Each ROI was con-
sidered as a contact and the number of contacts (number of
ROIs) referred to the total area measured (n∘ contacts/mm2).
Total length of contacts (𝜇m) was quantified by adding the
length of each individual ROI.
To perform the statistical analyses of the data, GraphPad
Prism4 forMacwas used. Statistical significancewas assessed
by one-wayANOVA followed by least significance differences
test. Data are represented as mean ± standard deviation, and
differences are considered significant at 𝑃 < 0.05. Asterisks
over the bars indicate statistically significant differences
versus control.
3. Results
3.1. Histological Analysis of Brain Injury. Haematoxylin-eosin
staining of the brainswas done, at 60 days, in order to evaluate
the histology of the tissue. We found that untreated animals
showed a perfectly delimited cystic cavity (Figure 1(a)), while
LA treated animals showed an uneven edge of the injury
(Figure 1(b)). These results are in agreement with those
obtained previously by our group where we found that the
LA treatment avoided the formation of the glial scar and
produced growing of the neural tissue inside the cystic cavity
[10].
3.2. Glial Reactivity after Brain Injury. As has been seen
before, our group has previously reported that the short-term
effects of LA avoid the glial scar formation after the brain
injury [10]. With the aim of evaluating the long-term astro-
glial reactivity after the brain injury, immunohistochemistry
for GFAP (astrocytes) was carried out 60 days after the injury.
In this case, untreated group (Figure 2(a)) still showed a
marked astroglial scar in the injury limit while LA treated
group (Figure 2(b)) presented a few astrocytes randomly
distributed across de adjacent tissue. Moreover, a statistically
significant decrease (𝑃 < 0.05) in the density of astroglial
cells (Figure 2(c))was shown in LA treated animals compared
with nontreated animals.
3.3. Blood-Brain Barrier Formation after Brain Injury. It has
been previously described that the BBB is affected after a
TBI [3]. In order to evaluate the organization of the BBB,
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Figure 4: Immunocytochemistry for Iba1 (microglia) at 15 and 60 days in nontreated animals ((a) and (c), resp.) and LA treated animals ((b)
and (d), resp.). Quantification of microglial cell density (n∘ cells/mm2) (e). Scale bar: 100𝜇m. ∗∗∗𝑃 < 0.001.
immunohistochemistry for Collagen IV (blood vessels) and
GFAP (astrocytes) was done in control animals (Figure 3(a)),
untreated animals (Figure 3(b)), and LA treated animals
(Figure 3(c)) 15 days after the injury.The quantification of the
number of contacts (n∘ contacts/mm2) established between
astrocytes and blood vessels (Figure 3(d)) showed that both
untreated and LA treated groups presented a statistical
significant increase (𝑃 < 0.01 and𝑃 < 0.001, resp.) compared
with control group. Moreover, LA treated group showed an
increase (𝑃 < 0.01) compared with untreated group.
In addition, when the total length (𝜇m) of the contacts
(Figure 3(e)) was measured, a statistically significant increase
was observed in both experimental groups (CR andCR+ LA)
compared with control group (𝑃 < 0.001).
3.4. Microglial Response. Microglial cells are the cell brain
responsible of the immune response. Those were revealed by
immunostaining with the marker Iba1 in order to see cell
morphology (Figure 4). Images taken 15 days after the injury
showed ramifiedmicroglia in untreated animals (Figure 4(a))
but amoeboid microglia cells were present in LA treated
group (Figure 4(b)). On the other hand, images taken at
60 days revealed amoeboid microglial cells in both groups
(Figures 4(c) and 4(d)). The quantification of the density
of Iba1 positive cells (Figure 4(e)) showed a statistically
significant increase in both experimental groups 15 days after
the injury (𝑃 < 0.001) but showed no statistical differences
after 60 days.
In addition, phagocytic cells were evaluated through
immunohistochemistry for ED1 15 and 60 days after the
injury (Figures 5(a)–5(d)). The quantification of the density
of cells (n∘ cells/mm2) (Figure 5(e)) showed a statistically
significant increase in both experimental groups 15 days after
the injury (𝑃 < 0.01 and 𝑃 < 0.001, resp.). Moreover, these
phagocytic cells were statistically significantly increased in
LA treated group compared with nontreated group (𝑃 <
0.05). Despite that, after 60 days, an increase in the density
of ED1 positive cells was observed in untreated animals,
reaching the same values as LA treated animals.
4. Discussion
After a TBI, inflammatory molecules from injured and dead
cells are released to the extracellular medium, which elicits
microglia and astroglia activation [2, 10].
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Figure 5: Immunofluorescence for ED1 marker (red) at 15 and 60 days in nontreated animals ((a) and (c), resp.) and LA treated animals ((b)
and (d), resp.). Nuclei become evident with Dapi (blue). Quantification of cell density (n∘ cells/mm2) of activated microglia/macrophage (e)
Scale bar: 200𝜇m. ∗∗𝑃 < 0.05; ∗∗𝑃 < 0.01.
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Astrocytes respond to all forms of CNS insults through
a process referred to as reactive astrogliosis [16]. It is well
documented that the reactive astrocytes undergo hypertro-
phy; upregulate intermediate filaments composed of nestin,
vimentin, and glial fibrillary protein (GFAP); and give rise to
the glial scar [17]. Previous studies of our group showed that
LA decreases the astroglial reactivity and avoids the glial scar
formation 15 days after the brain injury [10]. In the present
work we have shown that the glial scar still remains even 60
days after the injury while LA treatment avoids completely
the scar formation in the long term and astroglial cells are
randomly distributed across the adjacent tissue.
Moreover, it has been reported that the secondary damage
detached from TBI contributes to the BBB disruption [7].
Herein, we have seen that LA promotes the formation of
contacts between the endothelial cells and astrocytes, but we
have shown that the length of contacts is increased after a
TBI. Despite these findings were are not able to say if there
is a restoration of the BBB; however some authors affirm that
the use of LA on TBI and stroke animal models showed a
restoration of the BBB disruption and normalization of the
astrocytic/microglial activation and GSH levels [7–9].
Otherwise, activation of the immune system in the CNS
has become increasingly recognized as a key component of
the normal process of aging and also of the pathological
onset and progression ofmany neurological disorders includ-
ing TBI and neurodegenerative diseases [18]. Engulfment
of apoptotic cells has traditionally been attributed to pro-
fessional phagocytes, such as macrophages, microglia, and
dendritic cells [16]. Recent advances in microglial biology
have revealed thatmicrogliamay have important homeostatic
functions [19]; in normal brain they are very active in
surveillance of the normal neuronal environment and are
the first cells to respond to any subtle changes [20]. It is
well known that, under pathological conditions, microglia
are rapidly activated and expanded in population to respond
to the injury or stimulus. While ramified microglia are not
in physical contact to each other, some authors have argued
that their distribution within the brain allows them to “sense”
their immediate surroundings. Individual cells could then
respond to chemical or mechanical signals to activate the
response to injury [21].
Herein, we have identified microglia morphology, to
discriminate ramified microglia (resting) and amoeboid
microglia (phagocytic). We have seen that microglia
increased at 15 days and decreased at 60 days after the
brain injury. However, only untreated group at 15 days
showed ramified microglia. In addition, phagocytic cells
were significantly increased in LA treated group at 15 days,
while untreated group showed an increase at 60 days. In
view of these results, we hypothesize that LA administration
after brain injury avoids the glial scar formation, promoting
the restoration of the tissue through early immune response
developed by microglia.
Even though there is currently an open question about
the role of the microglial cells, in general, it is evident
that microglia play both detrimental and beneficial roles
in brain injury, depending upon the time and severity of
the inflammation. But on the other hand, there is also
growing evidence showing that, under certain circumstances,
microglia could be neuroprotective [22–24] and promote
adult neurogenesis [25, 26]. However, it has been reported
that innate immune response can also be beneficial in brain
ischemia [27, 28]. Indeed, microglia have been shown to be
neurosupportive by the uptake of glutamate [29], the removal
of cell debris [30], and the engulfment of polymorphonuclear
neutrophiles [31].
These findings, supported by our previous results, sustain
LA treatment as a new regenerative strategy after brain injury
and maybe other neurodegenerative diseases. However more
studies should be done on themicroglia response to clarify its
role in this field.
5. Conclusion
Herein, we have reported that LA administration avoids the
glial scar formation in the long term and promotes the BBB
formation. Moreover, increases the microglial population
early, but those decreases 60 days after the injury. In addition,
early phagocytic cell appears close to the injury when LA is
administered, while its absence delays the immune response
activation and restoration of the tissue. All these findings
lead us to better understanding of the immune response in
the CNS after brain injury and represent a crucial step to
the development of appropriate strategies against brain injury
and other degenerative diseases.
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